Big Law

Pfizer Acquires ReViral For $525 Million

Goodwin advised ReViral on the deal.

ReViral announced its acquisition by Pfizer. Pfizer will acquire ReViral for a total consideration of up to $525 million, including up front and development milestones.

ReViral is a privately held clinical-stage biopharmaceutical company focused on discovering, developing, and commercialising novel antiviral therapeutics that target respiratory syncytical virus (“RSV”). RSV is a respiratory pathogen, which can lead to severe and life-threatening lower respiratory tract infections in high-risk populations, including young infants, immunocompromised individuals, and older adults. It is estimated to cause infections in approximately 64 million people, resulting in about 160,000 deaths, globally each year.

Read the source article at globallegalchronicle.com

Leave a Review or Comment

Back to top button